Phase II and Coagulation Cascade Biomarker Study of Bevacizumab with or without Docetaxel in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma

PURPOSE: Treatment options are limited for advanced pancreatic cancer progressive after gemcitabine therapy. The vascular endothelial growth factor (VEGF) pathway is biologically important in pancreatic cancer, and docetaxel has modest anti-tumor activity. We evaluated the role of the anti-VEGF anti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Astsaturov, Igor A., Meropol, Neal J., Alpaugh, R. Katherine, Burtness, Barbara A., Cheng, Jonathan D., McLaughlin, Sue, Rogatko, André, Xu, Zhiheng, Watson, James C., Weiner, Louis M., Cohen, Steven J.
Format: Artigo
Jezik:Inglês
Izdano: 2011
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3030655/
https://ncbi.nlm.nih.gov/pubmed/20458210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0b013e3181d2734a
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki